Global Blood Therapeutics
South San Francisco
About Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and is headquartered in San Francisco, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $969.5M
- Funding stage: M&A
- Last round: Post-IPO Debt (Dec 2021)
- Ticker: nasdaq:GBT
- Website: gbt.com
- Phone: 650-741-7700
Industries & Categories
Biotechnology, Genetics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/global-blood-therapeutics-8416 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.